Posts

Showing posts with the label DED

Opioid-Induced Constipation (OIC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Opioid-induced constipation (OIC) is defined as new or worsening of constipation symptoms after initiating, increasing, or modifying opioid therapy and is common in patients on chronic opioid therapy. OIC is primarily mediated through the effects of opioids on μ-receptors in the gastrointestinal tract, reducing bowel tone, contractility, and luminal fecal moisture. ·        The prevalence of opioid-induced constipation (OIC) was 12.6%. Opioid-induced constipation (OIC) accounts for over 40% to 60% of patients without cancer receiving opioids. Thelansis’s “Opioid-Induced Constipation (OIC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Opioid-Induced Constipation...

Endometrial Carcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Endometrial carcinoma, also called Endometrial cancer ,  starts in the cells of the inner lining of the uterus (the endometrium). It is the most common type of uterus cancer. Thelansis’s “Endometrial Carcinoma Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometrial Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Endometrial Carcinoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. Endometrial Carcinoma Market ...

Eosinophilic Gastritis or Gastroenteritis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Eosinophilic esophagitis is the most commonly recognized EDD. Patients often present with symptoms similar to gastroesophageal reflux disease; however, they are not responsive to traditional antireflux therapy. Emerging data suggest that using acid-suppressive medications may predispose patients to develop eosinophilic esophagitis. The alteration of gastric pH caused by antisecretory medications has been shown to affect protein digestion, allowing a larger percentage of ingested protein to be absorbed in larger fragments, potentially inducing an immunologic response. The diagnosis of eosinophilic esophagitis relies on endoscopic biopsy. Visualization of the esophagus during endoscopy may appear abnormal, including esophageal furrows and strictures, white plaques, or mucosal rings. However, in one-third of patients, the appearance of the esophagus may be normal. ·        The reported incidence is approximately 6.5 to 7.8 cases per 100,000 population....

Clear Cell Sarcoma (CCS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Clear cell sarcoma (CCS) is a rare type comprising approximately 1% of all soft tissue sarcomas. Clear cell sarcoma is localized mainly in the lower limbs, with most cases localized in the area of the foot and ankle, where up to 40% of tumours are located. The upper limb is affected in 25% of cases. Primary CCS tumours usually develop deeply in soft tissues adjacent to tendons, fasciae, or dissections. CCS can develop at any age. However, several cases of CCS have been diagnosed over 40 years. Despite slow growth and latent progression, CCS is characterized by high aggressiveness — in about 30% of patients, lymph nodes or distant metastases are present at the time of diagnosis. Unlike most sarcomas that metastasize via the circulatory system, approximately 50% of patients with CCS present with metastases in the lymph nodes. ·        The vast majority of categories of sarcomas had an incidence case ranging between 1 to 5 cases per 1,000,000. The most...

Basal Cell Carcinoma (BCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Basal Cell Carcinoma (BCC) (also called basal cell skin cancer) is generally defined as a locally invasive, slowly spreading tumor that rarely metastasizes, arising in the epidermis or hair follicles. The main etiological factor responsible for BCC is chronic UV exposure at the expense mostly of UVB rays with a length of 290-320 mm. This results in activating proto-oncogenes and inactivating tumor-suppressive genes in the keratinocytes. ·        Basal Cell Carcinoma (BCC) is quite common, and the number of reported cases in the U.S. has steadily increased. The incidence of BCC is about 2000 cases per 100 000 population. More than 4 million Americans are diagnosed with BCC each year. Thelansis’s “Basal Cell Carcinoma (BCC) Market Outlook, Epidemiology , Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, reg...

Alcoholic Hepatitis (AH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Alcoholic hepatitis (AH) is an acute life and health-threatening disease. The clinical syndrome of jaundice and liver failure in alcohol abusers is typically called “acute alcoholic hepatitis” or “alcoholic hepatitis”, which is the most severe manifestation of the alcoholic liver disease spectrum. The clinical presentation of AH is heterogeneous and ranges from mild to severe. AH is often associated with systemic inflammatory response syndrome (SIRS) and moderate fever, with or without infection. Up to thirty-five percent of all heavy drinkers will have signs of alcoholic steatohepatitis in liver biopsies even though they may never develop the clinical syndrome. There are no standards or international consensus on the diagnostic criteria for AH. The combination of normal to mildly elevated aminotransferases, a total serum bilirubin level of more than 80 μmol per litre, an elevated INR, and neutrophilia with a history of heavy alcohol use is suggestive of AH. Thelansis’s “Alcohol...